Eli Lilly and Company announced Zepbound (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company’s digital healthcare platform. This update builds on Lilly’s ongoing efforts to lower out-of-pocket costs for people living with obesity in the United States. Last month, Lilly announced lower prices for Zepbound multi-dose pens, subject to approval by the US Food and Drug Administration (FDA). By lowering prices of Zepbound single-dose vials, Lilly is offering patients greater access and optionality with their treatment options.

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as USD 299 per month. The 5 mg dose will be available at USD 399 per month. All other approved doses are USD 449 per month for patients in the Zepbound Self Pay Journey Programme.  

“Far too many people who need obesity treatments still face cost and coverage barriers. Today’s action underscores Lilly’s commitment to improving access across the obesity care landscape. We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need,” said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities.

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. It may also help adults with moderate-to-severe Obstructive Sleep Apnea (OSA) and obesity to improve their OSA. It contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.

Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen (autoinjector). The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses are 10 mg or 15 mg for OSA.